News | March 14, 2026
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
The approval comes after a systematic review of published literature
Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention
Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
The recommendation is based on new data from continuous safety monitoring of medicines in the EU
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Subscribe To Our Newsletter & Stay Updated
